MedTrace Logo

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

NCT06138587 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-01-02

No results posted yet for this study

Summary

The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MPN) overlap syndrome after a standard-of-care stem cell transplant.

Names of the study therapies involved in this study are:

* CIML NK cells intravenous infusion (cellular therapy)
* Subcutaneous Interleukin-2 (recombinant, human glycoprotein)

Conditions

Interventions

BIOLOGICAL

Cytokine Induced Memory-like Natural Killer Cells

Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.

BIOLOGICAL

Interleukin-2

Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous injection per protocol.

Sponsors & Collaborators

Principal Investigators

  • Roman Shapiro, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-24
Primary Completion
2027-02-28
Completion
2027-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06138587 on ClinicalTrials.gov